Allergan PLC. (NYSE:AGN) – Equities research analysts at William Blair decreased their Q3 2017 EPS estimates for Allergan PLC. in a research report issued on Wednesday. William Blair analyst T. Lugo now expects that the company will earn $4.03 per share for the quarter, down from their prior estimate of $4.44. William Blair also issued estimates for Allergan PLC.’s Q4 2017 earnings at $4.84 EPS, FY2017 earnings at $16.24 EPS, FY2018 earnings at $17.37 EPS, FY2019 earnings at $18.90 EPS and FY2020 earnings at $20.60 EPS.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The firm had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the prior year, the firm posted $3.35 earnings per share. The company’s revenue for the quarter was up 8.8% on a year-over-year basis.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.watchlistnews.com/q3-2017-eps-estimates-for-allergan-plc-cut-by-william-blair-agn/1616456.html.

Other research analysts have also recently issued reports about the company. Vetr raised Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price objective on the stock in a research report on Monday, June 26th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $280.00 price objective (up from $270.00) on shares of Allergan PLC. in a research report on Wednesday, August 9th. UBS AG reaffirmed an “outperform” rating and set a $275.00 price objective on shares of Allergan PLC. in a research report on Wednesday, August 9th. Deutsche Bank AG reaffirmed a “buy” rating and set a $273.00 price objective (up from $265.00) on shares of Allergan PLC. in a research report on Monday, July 17th. Finally, Royal Bank Of Canada set a $284.00 price objective on Allergan PLC. and gave the company a “buy” rating in a research report on Sunday, July 16th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the company’s stock. Allergan PLC. currently has an average rating of “Buy” and a consensus target price of $271.64.

Shares of Allergan PLC. (NYSE:AGN) opened at 206.75 on Friday. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80. The stock has a market capitalization of $69.12 billion, a P/E ratio of 6.30 and a beta of 1.15. The stock has a 50 day moving average of $218.50 and a 200-day moving average of $233.15.

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Friday, August 18th were issued a dividend of $0.70 per share. The ex-dividend date was Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.35%. Allergan PLC.’s dividend payout ratio (DPR) is 9.95%.

Allergan PLC. declared that its board has authorized a stock buyback plan on Monday, September 25th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 2.8% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s board believes its stock is undervalued.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AGN. Howard Hughes Medical Institute bought a new position in shares of Allergan PLC. during the 2nd quarter valued at approximately $103,000. Jacobi Capital Management LLC increased its position in shares of Allergan PLC. by 4.9% during the 1st quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after purchasing an additional 22 shares during the last quarter. JNBA Financial Advisors increased its position in shares of Allergan PLC. by 2.5% during the 1st quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after purchasing an additional 12 shares during the last quarter. Massey Quick & Co. LLC increased its position in shares of Allergan PLC. by 334.8% during the 2nd quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after purchasing an additional 385 shares during the last quarter. Finally, Pacific Center for Financial Services increased its position in shares of Allergan PLC. by 805.1% during the 1st quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock valued at $128,000 after purchasing an additional 475 shares during the last quarter. 82.03% of the stock is currently owned by hedge funds and other institutional investors.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Earnings History and Estimates for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.